Solid financials from Stada but outlook sends stock down

25 March 2014

German generic and branded drugmaker Stada Arzneimittel (SAZ: GR) posted a solid set of financial results for 2013, but saw its shares plunge 15% to 29.40 euros by close of trading yesterday, as the company warned of a poor outlook as a result of uncertainties in Russia and Ukraine.

Stada group sales for the year increased 10% to 2.01 billion euros ($2.78 billion) and exceeding the two billion euro mark for the first time in the company’s history.

Sales of the core Generics segmentshowed a rise of 2% to 1.23 billion euros, thereby contributed 61.3% to group sales (previous year: 66.0%). Sales of the core segment Branded Products leapt 19% to 708.5 million euros in 2013.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK